Ryan Kruger joins Anagenex, a cutting-edge platform company marrying Machine Learning with DNA-encoded libraries to discover the next generation of small molecule medicines at scale. Anagenex, a Lux investment, recently closed a $30 million Series A financing round led by Catalio Capital Management.
Kruger joins Anagenex from Foghorn Therapeutics, a clinical-stage biotech, where he served as Vice President, Head of Biology overseeing all aspects of discovery biology, translational medicine, and early clinical development. Previously, Ryan spent fifteen years at GSK, most recently as Vice President, Head of the Cancer Epigenetics Research Unit, Oncology R&D where he shepherded six novel small molecule therapies from discovery to clinical development.
In Kruger, Anagenx captures a creative drug hunter with a demonstrated record of success assembling robust pipelines of programs and pushing them forward into the clinic in both large and small company settings. As CSO, Ryan will partner closely with Joe Franklin, SVP & Head of Early Discovery, whom Occam also placed at Anagenex in 2020. Finally, Kruger will doubtlessly benefit from wisdom at the Board level in Tito Serafini whom Occam also placed in 2020.
Occam’s enduring relationship with LabGenius, a UK-based AI-enabled protein drug discovery platform company, has yielded a second C-suite placement in Leo Wossnig as CTO. Leo will work in close partnership with Gino Van Heeke, the CSO, whom Occam placed as CSO in 2021.
Wossnig comes to LabGenius by way of Odyssey Therapeutics following the acquisition of his company, Rahko, a leading quantum machine learning company which Leo co-founded and led as CEO.
In Wossnig, LabGenius captures an intellectual heavyweight, content expert and accomplished entrepreneur with demonstrated success building and leveraging sophisticated computational technologies in the service of expediting drug discovery at scale.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies, has appointed John F. McDonald to its Board.
John currently serves as Corporate Vice President, Global R&D Business Development, for Novo Nordisk A/S, where he leads R&D business development activities and investment strategies. From 2011 to 2018, John was Vice President, Business Development, at Biogen Inc. and prior to that role, served as Managing Director at MPM Capital LP. His earlier career includes roles across business development, corporate strategy, and legal at various biopharmaceutical companies.
John holds a J.D. from University of California Hastings College of the Law and an M.B.A. and B.S. from the Haas School of Business, University of California, Berkeley.
Geron is a longstanding client for whom Occam had previously placed two independent Board members, Dawn Bir and Liz O’Farrell, and more recently, Chief Business Officer Edward Koval and VP Investor Relations & Corporate Communications Aron Feingold.
Bimal Shah joins Corium, a commercial-stage CNS biopharma and Gurnet Point Capital investment, as Chief Financial Officer, bringing with him substantial experience in healthcare private equity investments, M&A, and other strategic transactions. He also has industry experience in corporate strategy and commercial assessments with expertise in specialty pharmaceuticals, biotech, medical devices, contract research and manufacturing services, clinical and lab services, and distribution.
Prior to joining Corium, Bimal served as Senior Vice President, Corporate Finance and Strategy, for Sumitovant Biopharma, a wholly-owned subsidiary of Sumitovant Dainippon Biopharma, one of Japan’s largest pharmaceutical companies. While at Sumitovant, he had oversight for financial planning and analysis, corporate finance and strategy, among other responsibilities.
Bimal previously held roles in the business development, finance and strategic functions at various biotech companies, including Genentech. His earlier career occurred on Wall Street with Goldman Sachs and Warburg Pincus, where he focused on the life sciences and healthcare verticals and was responsible for a wide range of creative transactions, including financings, investments, acquisitions and alliances.
Bimal received his Master’s in Business Administration, Master of Arts in International Policy Studies and bachelor’s degrees from Stanford University.
Neomorph, an induced proximity platform company which raised a $109 Million A round led by Deerfield, has added Bell Zhong as Chief Financial Officer.
Neomorph is focused on solving critical problems in human health through the discovery and development of innovative new medicines against “undruggable targets.”
Zhong brings nearly two decades of investment banking and corporate finance leadership experience in the healthcare and life sciences sector. Bell joins Neomorph from Raymond James where he was Managing Director covering the biotechnology sector, responsible for advising companies of all stages of development on a wide array of financing and strategic transactions. Previously, Bell spent over 13 years at J.P. Morgan, where most recently he served as Executive Director in the firm’s leading Healthcare Investment Banking practice.
"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."Find out more Read the Case Study
"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."Find out more
"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."Find out more
"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."Find out more
“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”Find out more
Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.
Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.
The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.
Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.
Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.
Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.View all news